Event chart SAGE THERAPEUTICS, INC. |
|
|
Upcoming events on SAGE THERAPEUTICS, INC. |
|
08/03/22 | | Interim 2022 Earnings Release (Projected) |
11/02/22 | | Q3 2022 Earnings Release (Projected) |
02/23/23 | | FY 2022 Earnings Release (Projected) |
05/04/23 | | Q1 2023 Earnings Release (Projected) |
|
Past events on SAGE THERAPEUTICS, INC. |
|
06/16/22 | | Annual General Meeting |
06/13/22 | 06:20pm | | Goldman Sachs Global Healthcare Conference |
06/08/22 | 11:30am | | Jefferies Healthcare Conference |
06/01/22 | 08:00am | | Zuranolone Phase 3 SKYLARK Study Results Call |
05/11/22 | 11:00am | | Bank of America Healthcare Conference |
05/03/22 | 08:00am | | Q1 2022 Earnings Call |
05/03/22 | 06:30am | | Q1 2022 Earnings Release |
03/29/22 | 04:00pm | | Stifel CNS Day |
03/15/22 | | AD/PD Advances in Science & Therapy International Conference |
03/07/22 | 10:30am | | Cowen & Co. Health Care Conference |
|
Past dividends on SAGE THERAPEUTICS, INC. |
|
- No events available -
|
|
Fiscal Period : December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
Sales M $ |
Released Forecast Spread |
| 90,3 90,0 0,30% | 6,87 8,72 -21% | 1 114 7,04 15 717% | 6,31 6,48 -2,6% | 7,58 |
Operating income (EBITDA) M $ |
Released Forecast Spread | -273 -285 4,4% | -392 -375 -4,5% | -706 -736 4,0% | 627 -479 231% | -457 -456 -0,07% | -526 |
Operating profit (EBIT) M $ |
Released Forecast Spread | -273 -282 3,2% | -393 -369 -6,6% | -708 -728 2,8% | 624 -483 229% | -461 -463 0,43% | -526 |
Pre-Tax Profit (EBT) M $ |
Released Forecast Spread | -270 -279 3,0% | -373 -347 -7,4% | -680 -701 2,9% | 606 -471 229% | -458 -457 -0,11% | -522 |
Net income M $ |
Released Forecast Spread | -270 -279 3,3% | -373 -349 -6,8% | -680 -700 2,9% | 606 -473 228% | -458 -459 0,25% | -522 |
EPS $ |
Released Forecast Spread | -7,09 -7,38 3,9% | -8,08 -7,54 -7,1% | -13,4 -13,8 2,7% | 11,4 -9,07 226% | -7,80 -7,82 0,28% | -8,76 | Announcement Date | 02/22/2018 | 02/19/2019 | 02/27/2020 | 02/24/2021 | 02/24/2022 | - |
|
|
Fiscal Period : December | 2020 Q1 | 2020 Q2 | 2020 Q3 | 2020 Q4 | 2021 Q1 | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 |
Sales M $ |
Released Forecast Spread | 2,30 2,81 -18% | 1,09 0,88 24% | 1,64 1,85 -11% | 1 109 10,1 10 843% | 1,58 2,03 -22% | 1,64 2,01 -18% | 1,44 1,97 -27% | 1,64 1,77 -7,3% | 1,58 3,23 -51% | 1,74 | 1,86 | 2,17 | 2,46 | 2,68 |
Operating income (EBITDA) M $ |
Released Forecast Spread | -131 -178 26% | -110 -141 22% | -107 -137 22% | 974 -113 964% | -93,9 349 -127% | -107 -92,6 -16% | -131 -106 -23% | -125 -123 -1,9% | -119 -135 12% | -134 | -133 | -134 |
|
|
Operating profit (EBIT) M $ |
Released Forecast Spread | -132 -171 23% | -111 -141 22% | -108 -127 15% | 974 -48,5 2 106% | -96,5 -113 15% | -108 -102 -6,4% | -131 -110 -19% | -125 -129 3,0% | -123 -122 -1,1% | -129 | -133 | -140 | -143 | -143 |
Pre-Tax Profit (EBT) M $ |
Released Forecast Spread | -127 -167 24% | -136 -143 4,9% | -106 -127 17% | 975 -30,8 3 268% | -95,8 -108 11% | -107 -99,2 -8,1% | -130 -109 -20% | -125 -126 1,2% | -122 -121 -1,3% | -127 | -132 | -137 | -139 | -142 |
Net income M $ |
Released Forecast Spread | -127 -166 24% | -136 -140 2,6% | -106 -125 15% | 975 -115 951% | -95,8 -109 12% | -107 -99,1 -8,2% | -130 -108 -20% | -125 -128 2,6% | -122 -121 -1,0% | -127 | -131 | -137 | -139 | -142 |
EPS $ |
Released Forecast Spread | -2,44 -3,19 24% | -2,63 -2,69 2,3% | -2,03 -2,37 14% | 18,2 -1,05 1 828% | -1,64 -1,95 16% | -1,83 -1,68 -8,9% | -2,21 -1,85 -19% | -2,12 -2,17 2,1% | -2,07 -2,03 -2,1% | -2,15 | -2,23 | -2,33 | -2,37 | -2,34 | Announcement Date | 05/07/2020 | 08/10/2020 | 11/05/2020 | 02/24/2021 | 05/04/2021 | 08/03/2021 | 11/02/2021 | 02/24/2022 | 05/03/2022 | - | - | - | - | - | |
|
|
Upcoming sector events for SAGE THERAPEUTICS, INC. |
|
|
|
Past sector events for SAGE THERAPEUTICS, INC. |
|
|
|
|
|
Net sales (Year) - Rate of surprise
EPS (Year) - Rate of surprise
Net sales (Quarter) - Rate of surprise
EPS (Quarter) - Rate of surprise
|